inclusion criteria: 1. documented close contact with a person with either a pcr-confirmed sars-cov-2 or a positive rapid sars-cov-2 antigen test (as per standard of care). 2. enrolment of the participant no more than 7 days since last contact with index case; 3. ≥ 16 years of age; 4. informed consent as documented by signature (including parent's or legal guardian's signature if the participant is between 16 and 18 y.o.). exclusion criteria\*: 1. fever (temperature \>38.0°c) and/or respiratory symptoms (cough, dyspnea) and/or new anosmia/ageusia; 2. individuals with previous confirmed sars-cov-2 infection, dating within the last six months ; 3. known impairment of liver function; 4. known hypersensitivity to the study medications; 5. use of any medications that are contraindicated with lopinavir/ritonavir using the website www.hiv-druginteractions.org/checker 6. individuals on boosted protease inhibitor (other than lpv) or boosted elvitegravir as part of an antiretroviral therapy 7. inability to be followed-up for the trial period 8. documented vaccination against sars-cov-2 * where necessary, additional biological and clinical assessment will be performed, based on clinical judgement.

inclusion criteria: 1. documented close contact with a person with either a pcr-confirmed sars-cov-2 or a positive rapid sars-cov-2 antigen test (as per standard of care). 2. enrolment of the participant no more than 7 days since last contact with index case; 3. ≥ 16 years of age; 4. informed consent as documented by signature (including parent's or legal guardian's signature if the participant is between 16 and 18 y.o.). exclusion criteria\*: 1. fever (temperature \>38.0°c) and/or respiratory symptoms (cough, dyspnea) and/or new anosmia/ageusia; 2. individuals with previous confirmed sars-cov-2 infection, dating within the last six months ; 3. known impairment of liver function; 4. known hypersensitivity to the study medications; 5. use of any medications that are contraindicated with lopinavir/ritonavir using the website www.hiv-druginteractions.org/checker 6. individuals on boosted protease inhibitor (other than lpv) or boosted elvitegravir as part of an antiretroviral therapy 7. inability to be followed-up for the trial period 8. documented vaccination against sars-cov-2 * where necessary, additional biological and clinical assessment will be performed, based on clinical judgement.

inclusion criteria: documented close contact with a person with either a pcr-confirmed sars-cov-2 or a positive rapid sars-cov-2 antigen test (as per standard of care). enrolment of the participant no more than 7 days since last contact with index case; ≥ 16 years of age; informed consent as documented by signature (including parent's or legal guardian's signature if the participant is between 16 and 18 y.o.). exclusion criteria*: fever (temperature >38.0°c) and/or respiratory symptoms (cough, dyspnea) and/or new anosmia/ageusia; individuals with previous confirmed sars-cov-2 infection, dating within the last six months ; known impairment of liver function; known hypersensitivity to the study medications; use of any medications that are contraindicated with lopinavir/ritonavir using the website www.hiv-druginteractions.org/checker individuals on boosted protease inhibitor (other than lpv) or boosted elvitegravir as part of an antiretroviral therapy inability to be followed-up for the trial period documented vaccination against sars-cov-2 where necessary, additional biological and clinical assessment will be performed, based on clinical judgement.

inclusion criteria: documented close contact with a person with either a pcr-confirmed sars-cov-2 or a positive rapid sars-cov-2 antigen test (as per standard of care). enrolment of the participant no more than 7 days since last contact with index case; ≥ 16 years of age; informed consent as documented by signature (including parent's or legal guardian's signature if the participant is between 16 and 18 y.o.). exclusion criteria*: fever (temperature >38.0°c) and/or respiratory symptoms (cough, dyspnea) and/or new anosmia/ageusia; individuals with previous confirmed sars-cov-2 infection, dating within the last six months ; known impairment of liver function; known hypersensitivity to the study medications; use of any medications that are contraindicated with lopinavir/ritonavir using the website www.hiv-druginteractions.org/checker individuals on boosted protease inhibitor (other than lpv) or boosted elvitegravir as part of an antiretroviral therapy inability to be followed-up for the trial period documented vaccination against sars-cov-2 where necessary, additional biological and clinical assessment will be performed, based on clinical judgement.

inclusion criteria: 1. documented close contact with a person with either a pcr-confirmed sars-cov-2 or a positive rapid sars-cov-2 antigen test (as per standard of care). 2. enrolment of the participant no more than 7 days since last contact with index case; 3. ≥ 16 years of age; 4. informed consent as documented by signature (including parent's or legal guardian's signature if the participant is between 16 and 18 y.o.). exclusion criteria*: 1. fever (temperature >38.0°c) and/or respiratory symptoms (cough, dyspnea) and/or new anosmia/ageusia; 2. individuals with previous confirmed sars-cov-2 infection, dating within the last six months ; 3. known impairment of liver function; 4. known hypersensitivity to the study medications; 5. use of any medications that are contraindicated with lopinavir/ritonavir using the website www.hiv-druginteractions.org/checker 6. individuals on boosted protease inhibitor (other than lpv) or boosted elvitegravir as part of an antiretroviral therapy 7. inability to be followed-up for the trial period 8. documented vaccination against sars-cov-2 - where necessary, additional biological and clinical assessment will be performed, based on clinical judgement.

inclusion criteria: 1. documented close contact with a person with either a pcr-confirmed sars-cov-2 or a positive rapid sars-cov-2 antigen test (as per standard of care). 2. enrolment of the participant no more than 7 days since last contact with index case; 3. ≥ 16 years of age; 4. informed consent as documented by signature (including parent's or legal guardian's signature if the participant is between 16 and 18 y.o.). exclusion criteria*: 1. fever (temperature >38.0°c) and/or respiratory symptoms (cough, dyspnea) and/or new anosmia/ageusia; 2. individuals with previous confirmed sars-cov-2 infection, dating within the last six months ; 3. known impairment of liver function; 4. known hypersensitivity to the study medications; 5. use of any medications that are contraindicated with lopinavir/ritonavir using the website www.hiv-druginteractions.org/checker 6. individuals on boosted protease inhibitor (other than lpv) or boosted elvitegravir as part of an antiretroviral therapy 7. inability to be followed-up for the trial period 8. documented vaccination against sars-cov-2 - where necessary, additional biological and clinical assessment will be performed, based on clinical judgement.

inclusion criteria: 1. documented close contact with a pcr-confirmed sars-cov-2 positive individual 2. ≥ 16 years of age; 3. informed consent as documented by signature (including parent's or legal guardian's signature if the participant is 16 and 18 y.o.); exclusion criteria*: 1. fever (temperature >38.0°) and/or respiratory symptoms (cough, dyspnoea) and/or new anosmia/ageusia; 2. individuals with previous confirmed sars-cov-2 infection, dating within the last six months ; 3. known impairment of liver function; 4. known hypersensitivity to the study medications; 5. use of any medications that are contraindicated with lopinavir/ritonavir using the website www.hiv-druginteractions.org/checker 6. individuals on boosted protease inhibitor (other than lpv) or boosted elvitegravir as part of an antiretroviral therapy 7. inability to be followed-up for the trial period - where necessary, additional biological and clinical assessment will be performed, based on clinical judgement.

inclusion criteria: 1. documented close contact with a pcr-confirmed sars-cov-2 positive individual 2. ≥ 16 years of age; 3. informed consent as documented by signature (including parent's or legal guardian's signature if the participant is 16 and 18 y.o.); exclusion criteria*: 1. fever (temperature >38.0°) and/or respiratory symptoms (cough, dyspnoea) and/or new anosmia/ageusia; 2. individuals with previous confirmed sars-cov-2 infection, dating within the last six months ; 3. known impairment of liver function; 4. known hypersensitivity to the study medications; 5. use of any medications that are contraindicated with lopinavir/ritonavir using the website www.hiv-druginteractions.org/checker 6. individuals on boosted protease inhibitor (other than lpv) or boosted elvitegravir as part of an antiretroviral therapy 7. inability to be followed-up for the trial period - where necessary, additional biological and clinical assessment will be performed, based on clinical judgement.